#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gastrooesophageal cancer Hodgkin's disease Isodicentric chromosome 15 syndrome MELAS syndrome Hypersomnia Glycogen storage disease type V Precursor T-lymphoblastic lymphoma/leukaemia recurrent Leukocyte adhesion deficiency Follicular lymphoma stage III Acquired haemophilia Leukoencephalopathy Vernal keratoconjunctivitis Henoch-Schonlein purpura nephritis Uterine leiomyosarcoma Short stature More trials…

    Learn about Rare Diseases

    Hereditary angioedema Haemophilia A with anti factor VIII Encephalitis autoimmune – Treatment Splenic marginal zone lymphoma Lysosomal storage disorder – Treatment Ornithine transcarbamoylase deficiency – Treatment Andersen-Tawil syndrome – Treatment Alport’s syndrome – Diagnostics Primary hyperoxaluria – Life with Disease Andersen-Tawil syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ivermectin Tanimilast Ulipristal Acetate Human Vaccinia Immunoglobulin Monalizumab Triamcinolone Selpercatinib Vortioxetine Cladribine Pristinamycin Dc-806 Dacomitinib Mifepristone Purified Egg Phospholipids Posenacaftor IMELASOMERAN Ht-29-B PAPAVERINE HYDROCHLORIDE Sodium Phenylbutyrate Bidridistrogene Xeboparvovec More therapies…

    Learn about Your Condition

    Neck pain Cutaneous T-cell lymphoma Lung disorder Endocarditis bacterial Low cardiac output syndrome Seasonal allergy Vulvar dysplasia Hyperplasia adrenal Iron overload Diffuse large B-cell lymphoma Proteinuria Encephalopathy neonatal Optic ischaemic neuropathy Dyslipidaemia Hydrocephalus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University General Hospital Of Thessaloniki Ahepa

University General Hospital Of Thessaloniki Ahepa

1st St Kiriakidis Str, Thessaloniki, 546 36, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    • Gemcitabine
    • Lenalidomide
    Belgium Bulgaria Croatia Czechia France Greece +5

  • Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute haemorrhagic ulcerative colitis
    Investigated Drugs:
    • Sodium Chloride
    • Vedolizumab
    Bulgaria Croatia Czechia Greece Hungary Italy +5

  • Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Bulgaria Denmark France Germany Greece +5

  • Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

    Not recruiting

    4 1
    Investigated Drugs:
    • Bhv-7000
    Denmark Finland Germany Greece Hungary Italy +5

  • Study on Flecainide and Ranolazine for Restoring Heart Rhythm in Patients with Recent Atrial Fibrillation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Ranolazine
    • Flecainide Acetate
    Greece

  • Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Sotatercept
    Austria Belgium Croatia Czechia Denmark France +7

  • Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sotatercept
    Austria Belgium Croatia Czechia Denmark France +8

  • Study of GEN3014 and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Daratumumab
    Czechia Denmark Greece Hungary Poland Spain +1

  • Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Cyprus Czechia Denmark Finland France +9

  • Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia (in remission)
    Investigated Drugs:
    • Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu And Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly
    • Decitabine
    • Sargramostim
    France Germany Greece Italy Spain
Previous Page
1 … 9 10 11 12 13 … 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!